Home News
Keraplast will host a ~30 minute User’s Group Meeting at the Debra International Annual Congress in London during the lunch break on Friday 25th September.  People with EB, carers, nurses and doctors/dermatologists/physicians are welcome to attend and we aim to facilitate discussion about the use of keragel® & keragelT® and how to get the best possible treatment outcomes.  EB Nurses Jackie Denyer (UK) and Sharon Cassidy (NZ) have extensive experience using the products and they are keen and willing to share their knowledge and tips.   They have written a guidance booklet “keragel® & keragelT® In the Management of Epidermolysis Bullosa” which will be launched at this meeting.
Keraplast will also have a stand at the congress and staff will be available for meetings and discussions. Please encourage anyone with an interest in EB, either as a patient or as someone involved in care, to attend. We hope to see you there.
Posted in Company News |

Keraplast announced today extension of its distribution network for Replicine™ Functional Keratin® advanced wound care technology to include Singapore, Malaysia and Poland. Consistent with the company strategy to address unmet clinical needs in these regions through local specialist distributors, Keraplast has been identifying expert groups with a comprehensive understanding and relationships in the wound care sector. “While the core needs of the epidermolysis community around the world are consistently focused on wound care, how that care is delivered and paid for varies widely in each region” said Dr Clive Marsh, Keraplast Wound Care Development Manager. “Similar issues occur in the area of chronic wound care also. Working with local distributors who have the understanding to the address this quickly ensures that patients in need have the greatest opportunity of receiving the most advanced wound care technology quickly. We are proud to work with Rhema Speicalty Pharmaceuticals in Singapore and Malaysia and Support-Pharma in Poland. Both groups are focused on ensuring patients receive the best care available to and have the understanding to get that care delivered as quickly and efficiently as possible” he added.

Rhema Specialty Pharmaceuticals has been appointed as distributor for Singapore and Malaysia, for enquiries please contact http://rhemapharma.com/index.php +65 9739 2568, email: enquiries@rhemapharma.com.

Support-Pharma has been appointed as distributor for Poland, for enquiries please contact http://www.support-pharma.pl/ +48 519 109 402.

Posted in Company News |

The use of Replicine™ Functional Keratin® to advance wound care in conditions ranging from Epidermolysis Bullosa to chronic wound care and acceleration of healing of complex wounds will be presented at EWMA, London, May 13-15.

Keraplast products have regulatory approval and reimbursement status in an increasing number of European countries. Keraplast is looking forward to this opportunity to introduce the Replicine™ Functional Keratin® product range to innovative clinicians, and work with a rapidly expanding group of distribution partners in Europe.

Please join us at the forefront of wound care at booth 1-68 of EWMA  http://www.ewma2015.org/.

Poster Presentations:

An evaluation of a keratin gel to accelerate healing and improve care for dystrophic epidermolysis bullosa patients, G Tadini, MD, U.O.S. Dermatologia Pediatrica – Dipartimento di Medicina Interna e Specializzazioni Mediche, IRCCS Ospedale Maggiore, Milano, Italy.

A clinical trial of a keratin gel to accelerate healing and improve comfort post haemorrhoidectomy, I Kolossa, MD, EBSQ, Intus Digestive and Colorectal Care, Christchurch, New Zealand.

Keratin dressings in the management of epidermolysis bullosa, J Denyer, Great Ormond Street Hospital, London, United Kingdom.

Effectiveness of topical therapies based on keratin for pressure sore in spinal cord injury, M Belci, MD, T Simone, MD, PRM, R Singhal, MD, L Stephen, RN, National Spinal Injury Centre, Stoke Mandeville, United Kingdom, University of Roma Tor Vergata, Italy and Burwood Hospital Spinal Unit, Christchurch, New Zealand.

Novel use of a keratin gel to epithelise areas with delayed healing as part of a procedure for giant nevus. J Jutkiewicz-Sypniewska, MD, M Plewko, MD, Department of Paediatric Surgery, Children’s Hospital of Professor J. Bogdanowicz, Warsaw, Poland

Posted in Company News |

The use of Replicine™ Functional Keratin® to advance wound care in conditions ranging from Epidermolysis Bullosa to chronic wound care and acceleration of healing of complex wounds will be presented by clinicians at SAWC 2015, San Antonio, TX, USA, April 29-May 3.

Keraplast Technologies will be available for further discussion on the Replicine™ Functional Keratin®, the new paradigm in wound healing, at booth 252. Please join us at the forefront of wound care.

Poster Presentations:

An evaluation of a keratin gel to accelerate healing and improve care for dystrophic epidermolysis bullosa patients, G Tadini, MD, U.O.S. Dermatologia Pediatrica – Dipartimento di Medicina Interna e Specializzazioni Mediche, IRCCS Ospedale Maggiore, Milano, Italy.

A clinical trial of a keratin gel to accelerate healing and improve comfort post haemorrhoidectomy, I Kolossa, MD, EBSQ, Intus Digestive and Colorectal Care, Christchurch, New Zealand.

Keratin dressings in the management of epidermolysis bullosa, J Denyer, Great Ormond Street Hospital, London, United Kingdom.

Effectiveness of topical therapies based on keratin for pressure sore in spinal cord injury, M Belci, MD, T Simone, MD, PRM, R Singhal, MD, L Stephen, RN, National Spinal Injury Centre, Stoke Mandeville, United Kingdom, University of Roma Tor Vergata, Italy and Burwood Hospital Spinal Unit, Christchurch, New Zealand.

Novel use of a keratin gel to epithelise areas with delayed healing as part of a procedure for giant nevus. J Jutkiewicz-Sypniewska, MD, M Plewko, MD, Department of Paediatric Surgery, Children’s Hospital of Professor J. Bogdanowicz, Warsaw, Poland

Posted in Company News |

Keraplast Technologies announced today the appointment of SpringMedical of the Netherlands as its exclusive distribution partner for keragelT® for management of epidermolysis bullosa in the Netherlands, Belgium and Luxembourg. Dr Clive Marsh, Wound Care Development Manager for Keraplast, said “keragelT® is being increasingly used as the product of choice by clinicians and experts in management of epidermolysis bullosa all over the world, but in particular in the EU. To extend that availability to the Netherlands, Belgium and Luxembourg is a significant addition and we believe will be welcomed by families living with EB in this region.” Dr Rob Kelly, Interim Chief Executive of Keraplast added “increasing distribution for our Replicine™ Functional Keratin® wound care technology in the EU is a strategic goal for us, and our actions over the last 12 months have created a strong and stable foundation for future business growth with the majority of the EU now covered. We are proud to partner with SpringMedical as we believe they share our philosophy of delivering the best care available to meet this unmet clinical need and represent the best way to get keragelT® to families living with EB in the region” Harry Wierbos, Chief Executive of SpringMedical said “Families in the Netherlands, Belgium and Luxembourg expect the highest standard of care to be available to them. SpringMedical consistently provides products backed by strong clinical evidence to deliver that care and welcomes the addition of the innovative product keragelT® to its portfolio. The EB community in Benelux can continue to expect the latest wound care innovations to be available from SpringMedical.”

For enquiries from Netherlands, Belgium or Luxembourg please contact SpringMedical +31 55 3560544, http://www.springmedical.nl, h.wierbos@springmedical.nl.

Posted in Company News |

German medical distribution company Memax has been appointed as distributor for keragelT®, the advanced wound care product developed by Keraplast using its proprietary Replicine™ Functional Keratin® technology. Dr Clive Marsh, Wound Care Development Manager for Keraplast, said “We have been working for several years with specialist clinical groups and the international DEBRA organization to establish keragelT® as the best wound management option for patients living with epidermolysis bullosa. This includes groups in Germany and Austria as well as the UK and many Scandinavian countries. As more expert groups take on keragelT® as an important wound management tool, it is essential to be able to get keragelT® to patients in a practical and efficient way. We are very excited about joining with Memax to help this happen for the families in Germany and Austria.” Dr Rob Kelly, Interim Chief Executive of Keraplast added “To make a difference in the management of EB our ground breaking keragelT® product has to be proven as effective in the hands Doctors, Nurses and the families dealing with wound care every day. In addition it has to be easily accessible and where possible covered by national reimbursement or insurance programmes. All these factors have come together in the US, UK, Australasia and several other countries. With partnership with Memax we are confident the factors will align quickly for Germany also.”

Joachim Brinkmeir, CEO of Memax said “keragelT® is a highly innovative approach to epidermolysis bullosa wound management and is backed by a high standard of peer review data. This is very consistent with the high performance products that Memax has built a strong reputation on and we are excited to now be offering this to the clinical community in Germany.

For enquiries from Germany or Austria please contact brinkmeier@memax.de or visit http://www.memax.info/. From Germany phone 0761/1514668-0. From Austria or international phone 0049761/1514668-0.

Posted in Company News |

Keraplast and our distribution partners for keragelT® around the world would like to say thank you to the clinicians, nurses and families living with EB that have come to meet us over recent months. We have made many new friends and contacts, in the US at the DEBRA Patient Care Conference, in France at the DEBRA International Congress, in South Africa at the Dermatology Society of SA Annual Congress and in Norway at the Norwegian DEBRA national meeting.

As a result of feedback from people using keragelT® we have created this page of tips and tricks on how best to use keragelT® to manage EB wounds.

http://www.keraplast.com/tips-for-using-keragelt

We look forward to working more with DEBRA and the EB community in all of these regions. Latest information on keragelT® can always be found on our website here

http://www.keraplast.com/epidermolysis-bullosa

And by contacting us here

http://www.keraplast.com/contact

Posted in Company News |

San Antonio, USA, September 15th 2014. Keraplast announced today that a $1.6M grant had been awarded to the research institute AgResearch for a programme of research focused on keratin based wound care. The four year programme, led by senior scientist Dr Stefan Clerens from the Proteins and Biomaterials Team will extend knowledge of the bioactive performance of keratin proteins in a wound healing environment leading to the development of more advanced and higher performance keratin wound care devices to better address unmet clinical needs in wound care.

Keraplast Technologies is the commercial partner in the programme and collaborators include scientists from the University of Miami Miller School of Medicine.

Dr Rob Kelly, Keraplast Technologies Chief Scientific Officer and Interim Chief Executive Officer said “As the only company with keratin based wound care products in the market and in use in clinics around the world we are excited to be partnering with AgResearch in this scientific programme. We have consistently been at the forefront of keratin science and have a demonstrated track record of transforming that science into clinical benefits to make a difference to the lives of patients with unmet needs in wound care. This groundbreaking research from a world class team will ensure we maintain our position at the leading edge of applying keratin science in medicine.”

Dr Sonya Scott, key senior scientist in the programme, said “This is extremely exciting research, as it is a combinations of insight in biological modes of action and direct commercial application with real health outcomes. A core strength of AgResearch is the translation of excellent science into commercial outcomes, and working with the Keraplast team, and our collaborators at the University of Miami, will ensure that continues.”

Dr Stefan Clerens, Science Team Leader in the Proteins and Biomaterials Team added “The Protein and Biomaterials Team is world class in the field of keratin science and proteomics. Gaining the support from the government recognizes that expertise and gives us the foundation to further elucidate the biological mechanisms and performance of keratin proteins and peptides.”

The grant has been awarded under the High-Value Manufacturing and Services Research Fund as part of the Ministry of Business, Innovation & Employment and is for research commencing in October 2014.

For more information contact Rob.Kelly@keraplast.com or Stefan.Clerens@agresearch.co.nz.

Posted in Company News |

San Antonio, USA, July 10th 2014. Keraplast Technologies announced today that following evaluation at the specialist epidermolysis bullosa clinic at Great Ormond Street Hospital in London under the supervision of leading DEBRA Nurse Jackie Denyer, the keratin wound care gel keragelT® has been placed on the UK drug tariff list. This means clinicians and carers in the UK can now choose keragelT®, the latest tool for EB wound management, and have confidence that the care will be funded by the NHS.

In addition, H&R Healthcare has been appointed as UK distributor for the Keraplast wound care product range, including the keratin based products keragelT®, keragel®, keramatrix® and kerasorb®. This means that the only keratin based wound care products on the market are now available through the leading supplier of specialist wound care innovations in the UK.

Dr Rob Kelly, Interim Chief Executive Officers of Keraplast Technologies said “The unique approach to wound care that Replicine Functional Keratin provides is clearly solving unmet clinical needs in several disciplines, leading to growing interest in Europe. We are very pleased to be able to make a difference in the management epidermolysis bullosa and work closely with specialist clinics such as Great Ormond Street Hospital in London and EB Haus in Austria. Having keragelT® funded on the UK Drug Tariff will make a significant difference to families in the UK living with EB as they now have the latest advancement available to them. We are also seeing strong interest from groups working at the forefront of chronic wound care, such as the pressure ulcer group at Stoke Mandeville hospital who recently presented work on keragel® and keramatrix® at the 16th National Congress on Paraplegic Medicine in Italy.” He added “partnering with H&R Healthcare is perfect for us as they are clearly well recognised as being specialists at bringing wound care innovations into the UK healthcare system and we share the common goal of using innovation to improving patient outcomes.”

Mike Hoskins, Chief Executive Officer of H&R Healthcare said “our philosophy is

to offer innovative products that give the best overall value to the NHS, measured by patient outcomes and overall cost effectiveness. The Keraplast product range clearly provides this and we are excited about introducing this innovation to the UK.”

For product enquires from the UK please contact H&R Healthcare Ltd, Tel: +44 (0)1482 631606, Email: info@hrhealthcare.co.uk, web http://www.hrhealthcare.co.uk/index.html

Posted in Company News |

Replicine™ Functional Keratin® advanced wound care technology is now available in Denmark, Norway and Sweden following appointment of Med-Vice (Denmark and Norway) and MedPre AB (Sweden) as distributors of Keraplast wound care products.

Dr Rob Kelly, Interim Chief Executive of Keraplast said “health care in Scandinavia is well recognized as among the best in the world. The improved clinical outcomes available using Replicine Functional Keratin wound care products, in particular in management of epidermolysis bullosa, but also in care for chronic wounds and burns, is creating demand from clinicians in these regions that are used to providing their patients the best care available. We are pleased to have found local partners that are respected by the health care community and understand well how to get the best care to patients as easily as possible.”

Marie Louise Little, CEO of Med-Vice said “Interest in keragelT from the epidermolysis bullosa community is very high in many parts of Europe, including Denmark and Norway. Local clinicians always want to offer the best care, in particular to those in most need such as families living with EB and we are excited to now have that option available”

Magnus Precht, CEO of MedPre said “Replicine Functional Keratin is truly innovative and is well supported with published clinical data. It complements well the other advanced innovation that Med Pre offers to the wound care community and we are already seeing strong interest from the clinical community”

For enquires from Denmark or Norway contact Med-Vice on +45 4576 7626, www.med-vice.com or info@med-vice.com

For enquiries from Sweden contact MedPre AB on +46-708-205041 or at www.medpre.se.

Posted in Company News |